



Kabra Drugs Limited

CIN NO : L02423MP1989PLC005438

Regd Off: 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh – 452 011. Phone : +91 9884624100

To
BSE Limited
Phiroze Jeejeebhoy Towers
21st Floor, Dalal Street
Mumbai – 400 001

June 18, 2025

Sub.: Outcome of the Board Meeting and disclosure under Regulation 30 of SEBI(Listing Obligations & Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e 18th June 2025, inter-alia, considered and approved the following:

1. The board has approved and authorized Mr. N. Aravind (Managing Director) to complete the acquisition of AMR PHARMA INDIA PRIVATE LIMITED and also the board has requested the managing director to inspect and formulate a strategy to acquire BONN SCHTERING BIO SCIENCES in Pondicherry.
2. The board is happy to announce that they have received permission from FDA to manufacture and sell license for our Chennai facility.
3. The board has decided to establish a subsidiary to diversify into Artificial Intelligence and Machine Learning application for Pharmaceutical Sector, Qualitative Drug Monitoring & Clinical Research, Medical Imaging, Gene Mapping, Diagnostics and Health Care Sector. The subsidiary will also cater into E-Pharmacy and Medical Tourism Sector.
4. The board has authorized Mr. N. Aravind to appoint and sign agreements with senior state wise channel partners and district wise partners all over India to sell it own brand of medicines.

The meeting of the Board of Directors of the Company commenced at 05.00 p.m. (IST) and concluded at 06:30 p.m. (IST).

Kindly take the above intimation on your records.

Thanking you,

Yours sincerely,

For **Kabra Drugs Limited**



Managing Director